Blood Disorders Grants

National Hemophilia Foundation Judith Graham Poole Postdoctoral Research Fellowship

Letter of Intent Deadline: November 23, 2010
Application Deadline: February 23, 2011
Award Start Date: July 1, 2011

The program is named for Dr. Judith Graham Pool. In 1965, Dr. Pool discovered a simple method of extracting the clotting factor from human plasma. This opened the door to a series of rapid developments that revolutionized the treatment of hemophilia including replacement therapy. Replacement therapy (i.e., the infusion of the missing clotting factor to prevent or stop bleeding) has made it possible for people with hemophilia to live relatively normal and productive lives and to avoid, in large measure, the potentially crippling effects of the disorder.

Only noncommercial institutions and investigators associated with a noncommercial institution are eligible for NHF funding.

All grant and fellowship applications are subjected to a rigorous peer review process. Applications are critiqued on scientific merit and relevance to NHF research priorities. Applications are reviewed and scored in terms of significance, approach, innovation, investigator, and environment. A panel selected by the Research Working Group, a volunteer group of scientific and lay leaders, reviews applications received.

Eligibility
Applicants must have completed doctoral training and must enter the JGP fellowship program from a doctoral, postdoctoral, internship or residency training program. Established investigators or faculty members are not eligible. Applicants must be affiliated with domestic organizations such as universities, colleges, hospitals and laboratories. US citizenship is not required.

Permissible research topics include clinical or basic research on the biochemical, genetic, hematologic, orthopedic, psychiatric or dental aspects of the hemophilias or von Willebrand disease. Other topics include rehabilitation, therapeutic modalities, psychosocial issues, women's health issues, liver disease, or AIDS/HIV as they pertain to the hemophilias or von Willebrand disease.

It is expected that the fellow will spend at least 90% of the time on the research project for which funding is requested. The remaining 10% may be devoted to teaching or clinical work that is relevant to the research.

Funding
Support is available for up to $42,000/per year for a maximum of two years (pending continuing grant approval).

Letter of Intent
All interested candidates must submit a letter of intent by 5pm EST, November 23, 2010. This should be a brief letter identifying the researcher, their mentor, institution and a description of the proposed research project. Letters of intent should include an NIH-style CV or biosketch for both candidate and mentor. Letters of intent will be evaluated by members of NHF's Research Review Committee who will collectively decide upon the candidates invited to submit a full JGP application.

Inquiries
For further information, contact:

Angelina Wang
Director of Research and Medical Information
116 West 32nd Street, 11th floor
New York, NY 10001
Phone: (212) 328-3727 or (800) 42-HANDI ext. 3727
Fax: (212) 328-3799
E-mail: awang@hemophilia.org

International Myeloma Foundation Brian D. Novis Research Grant Program Junior Grant Award

Since 1990, the International Myeloma Foundation (IMF) has supported research through demographic analysis of risk factors to determine what causes myeloma. In 1994, the IMF established the Brian D. Novis Research Grant program to support investigators conducting cutting-edge studies to provide better treatment, management, prevention, and ultimately, a cure for myeloma.

The IMF offers grants to doctors and researchers working in the field of myeloma. All grant applications for funding in 2011 must be received by the IMF by August 31, 2010.

The International Myeloma Foundation funds several research grants including the Brian D. Novis Research Award. These grants are provided through donations from private individuals, and are presented annually by the International Myeloma Foundation. These awards go to doctors/researchers doing work in the field of multiple myeloma. This year's awards will be in the amount of $50,000. The Brian D. Novis Award honors the IMF’s founder Brian Novis, who died of multiple myeloma in July of 1992. The International Myeloma Foundation is a non-profit organization whose mission is to improve the quality of life for myeloma patients while working toward prevention and a cure.

QUALIFICATIONS
The qualifications for a candidate for the Brian D. Novis Research Award include the following:
• Completed postdoctoral studies or clinical fellowships not later than August 1 of the application year.
• Ability to devote a minimum of 50% of his or her time to the research project during the Award year.
• Ability to provide a completed application with evidence of a meritorious research project.
• Must complete and return application package to the IMF no later than August 31, 2010

International Myeloma Foundation

12650 Riverside Drive, Suite 206 | North Hollywood, CA 91607-3421

International Myeloma Foundation Brian D. Novis Research Grant Program 2011 Senior Research Award

Since 1990, the International Myeloma Foundation (IMF) has supported research through demographic analysis of risk factors to determine what causes myeloma. In 1994, the IMF established the Brian D. Novis Research Grant program to support investigators conducting cutting-edge studies to provide better treatment, management, prevention, and ultimately, a cure for myeloma.

The IMF offers grants to doctors and researchers working in the field of myeloma. All grant applications for funding in 2011 must be received by the IMF by August 31, 2010.

The International Myeloma Foundation funds several research grants including the Brian D. Novis Research Award. These grants are provided through donations from private individuals, and are presented annually by the International Myeloma Foundation. These awards go to doctors/researchers doing work in the field of multiple myeloma. This year’s awards will be in the amount of $80,000. The Brian D. Novis Award honors the IMF’s founder Brian Novis, who died of multiple myeloma in July of 1992. The International Myeloma Foundation is a non-profit organization whose mission is to improve the quality of life for myeloma patients while working toward prevention and a cure.

2011 Senior Research Award

QUALIFICATIONS
These awards are targeted to established investigators with a track record in myeloma or related research, and are designed for projects which represent a different focus, direction or area of research from those in which they are currently funded. In most cases, these awards will be for pilot projects to obtain sufficient funding for larger applications from NIH or similar larger funding agencies.

The qualifications for a candidate for the Brian D. Novis Senior Research Award include the following:
• Ability to provide a completed application with evidence of a meritorious research project.
• Must complete and return application package to the IMF no later than Tuesday August 31, 2010.

International Myeloma Foundation

12650 Riverside Drive, Suite 206 | North Hollywood, CA 91607-3421

American Society of Hematology Alternative Training Pathway Grant

The Alternative Training Pathway Grant is intended to foster the development and/or implementation of creative new curricula for trainees in clinical and clinical/translational hematology and related fields. A growing number of trainees are expressing an interest in pursuing hybrid careers (e.g., medicine/pediatrics) and/or a desire to become trained in both clinical care and laboratory medicine (e.g., transfusion medicine or directing hemostasis laboratories). There is a perceived need for specialists with integrated expertise in hematology and other rapidly evolving areas of applied medicine such as vascular biology, stem cell technologies, cellular therapeutics, and targeted pharmacotherapeutics, laboratory oversight, and transfusion medicine. The Alternative Training Pathway Grant is designed to allow training program directors the opportunity to develop curricula that meets these new demands. Examples of previously funded initiatives include integrated pathways in adult and pediatric benign hematology; pediatric hemostasis-thrombosis and pharmacology; and hematology and palliative care.

Support

Grants of up to $50,000 will be awarded to support the development and implementation of novel hematology-related training programs as an alternative to traditional training programs. The award may be expended over a one- to two-year period of time. No institutional overhead (i.e., indirect) costs will be supported by this grant.
Eligibility

Applicants must be Training Program Directors and other educators, and Active Members of the American Society of Hematology (ASH) at institutions with an accredited training program(s) in adult or pediatric hematology or hematology/medical oncology, or in other hematology-related disciplines (e.g., pathology specialties) in the United States, Canada, or Mexico. Awards are limited to only one application per institution. Awardees must commit to providing progress reports and final reports as defined in the terms of the grant.

Proposed Curriculum

The proposed curriculum should be able to integrate within an accredited hematology, hematology/oncology, and/or hematology-related specialty training program. Inter-disciplinary initiatives are encouraged, and multi-institutional programs will be considered.

Applicants should:

* Describe the proposed new or alternative training pathway(s).
* Discuss how career development and the scope of career opportunities will be enhanced through the proposed training pathway(s).
* If an inter-disciplinary initiative is proposed, describe how cross-training and certification in fields related to hematology may be pursued or how defined specialty barriers might be breached (e.g., medicine and pediatrics).
* Describe how the curriculum could be disseminated to other training programs if applicable.
* Describe plans to achieve sustainability of the pathway over time.

Examples of innovative pathways include: 1) Hematology and Laboratory Oversight Pathways (e.g. Special Coagulation Laboratory); 2) Hematology and Transfusion Medicine with an emphasis on apharesis.

Letter of Intent

Letters of Intent for the 2011 application cycle will be due via e-mail no later than 5:00 p.m. EST, on Tuesday, February 2, 2011. Those who have fulfilled the Letter of Intent requirements will be invited to apply.

Questions regarding this application and the ASH Alternative Training Pathway Grant should be directed to Joe Basso, Training Manager, at jbasso@hematology.org or 202-552-4910.

Audi Gerstein Platelet Disorder Scholarship for Undergraduate/Graduate Students with Platelet Disorders

Awards are restricted to senior high school students, current college students, or adults interested in
continuing education who have ITP or a similar inherited or non-inherited diagnosed platelet disorder.

The Scholarship award is intended to assist full-time undergraduate or graduate students entering or
attending an accredited technical school, two or four year college, university or graduate school in the
United States.

The Applicant must be a U.S. Citizen. There is no GPA requirement, however, the
applicant must have acceptance to the college of their choice. Former Scholarship recipients are not
permitted to reapply (those who have won book awards are eligible). Family members of ITP patients
or PDSA board members or Scholarship committee members are not eligible to apply.

The Process
A 700 – 1,000 word essay is required which details how your platelet disorder has resulted in your
growth as a person; what you learned about your own strengths and weaknesses. If you feel its
changed you, whether emotionally or physically, describe how it changed your approach to life and
relationships. Describe how having an illness might have affected your life's s accomplishments and
helped you set goals. If you feel that having a chronic illness has helped you choose a career path,
describe how, and explain why you feel this way and what you have done to meet these educational
goals. Explain what your plans are for the future in meeting your educational responsibilities, in light of
your struggles with a platelet disorder.

An Application will be due and submitted to the PDSA no earlier than March 15 and no later than
April 15. Awards will be announced by May 15. Incomplete or late Applications will not be considered.

Scholarship award winners will be announced on our website. The essays and applications will be
reviewed and judged by an impartial panel selected by the PDSA Board of Directors.

Scholarship Funds
Scholarship Funds will be awarded in a one-time payment of $1,000 during the academic year.
Payments will be made directly to the institution prior to the start of the fall semester.

Platelet Disorder Support Association
133 Rollins Avenue, #5
Rockville, MD 20852

Phone: 1- 87-PLATELET 877-528-3538 (toll free) or 301-770-6636

Fax: 301-770-6638 - e-mail: pdsa@pdsa.org

Conference Student Scholarships: Hematopoiesis

Scholarship Deadline: November 29, 2010 (Midnight US Mountain Standard Time)

As a paradigmatic model of developmental and regenerative biology, studies of the hematopoietic system have been critical in establishing fundamental principles in growth factor signaling, transcriptional regulation, organ patterning and stem cell biology. Yet, despite many recent ground-breaking discoveries in this field, the last Keystone Symposium on Hematopoiesis was held nearly 5 years ago, in 2004. Now, with new and emerging knowledge, we are beginning to develop a true molecular understanding of the mechanisms by which blood cells are created and maintained, and how their function may be perturbed in the context of hematopoietic deficiency and malignancy. In addition, sophisticated embryological studies have finally documented the existence of bipotential hemogenic endothelium in developing organisms, and striking technological advances in in vivo imaging and cell identification strategies have provided our first direct visualization of blood cell formation in situ, and indicated the key importance of cell migration and interaction with discrete niches in the direction of cell fate and function. Finally, when turned to the study of blood diseases, these tools have provided unexpected insights into the microenvironmental controls that regulate hematopoietic (dys)function during aging and malignancy. In light of these exciting developments, it is clear that the time has come to again bring together hematopoiesis researchers to facilitate and accelerate the exchange of new knowledge and ideas. Our proposed meeting will include a diverse group of scientists studying hematopoiesis with new technologies and complementary model systems. Speakers will be invited from all career stages, and talks will focus on current findings, emerging opportunities, and immediate challenges within the field. We expect this meeting to serve as a catalyst to develop new ideas and collaborations, and to enhance and encourage the creative and interactive science that will continue to push forward discoveries in this important area of research.

Keystone Symposia is offering scholarships to students and post-docs this conference season. These scholarships, of up to $1000 each, are to be used to help defray the expenses associated with conference attendance, including air (on a U.S. air carrier), ground transportation and lodging costs. Receipts will be required to receive reimbursement.

Abstracts submitted for poster presentation will be used as the basis for awarding the scholarships. Conference organizers will select the scholarship recipients based on the quality of science of the abstract and the relevance of the abstract to the conference topic. Only one application per abstract is accepted.

Keystone Symposia
221 Summit Place #272
PO Box 1630
Silverthorne, CO 80498
www.keystonesymposia.org

Financial Assistance / Student Scholarships
Phone: +1 (800) 253-0685 or
Ksenia Shambarger - +1 (970) 262-1230 extension 140
Fax: +1 (970) 262-0311

2010 Mantle Cell Lymphoma Correlative Clinical Studies Grant

* $100K per year for 2 years: The Lymphoma Research Foundation (LRF) Mantle Cell Lymphoma Consortium seeks proposals for correlative clinical studies in mantle cell lymphoma. Applications to this initiative must be an adjunct to a major MCL research project and work in the clinical setting or with primary MCL patient samples. Innovative research by definition may uncover new questions and new areas requiring investigation. Basic funding often does not allow for additional, correlative studies to explore these areas. The intention of the current request for proposals is to fund such adjunct studies to complement and synergize with ongoing MCL trials within the NCI Cancer Cooperative Groups and/or the LRF-funded clinical projects. The applications should clearly focus on MCL and have a high degree of relevance to research questions pertinent to MCL.

RESEARCH OBJECTIVES:
To be considered for funding, an adjunct study should be:
1. Associated with an ongoing, clinical research project focused specifically on mantle cell lymphoma and funded by LRF or the NCI.
2. Intended to test a new hypothesis based on preliminary findings in the major study.
3. Capable of furthering the understanding of mantle cell lymphoma and/or its diagnosis and treatment.
Examples of eligible projects include, but are not limited to:
--Molecular and/or genetic profiling of patient-derived samples
--Identification of biomarkers
--Immunological studies
• Establishment of tissue arrays and other archival resources

Applications to this initiative must work in the clinical setting or with primary MCL patient samples.

ELIGIBILITY:

You may submit an application if your institution is a:
--Non-profit organization
--Public or private institution such as a university, college, hospital and/or laboratory

--Domestic or foreign institutions/organizations are eligible

For-profit entities are not eligible to apply for LRF funds, however, should a for-profit institution have a relevant therapeutic or research project, they should contact LRF management to discuss possible public-private partnerships.

Any individual with the skills, knowledge and resources necessary to carry out the proposed research is invited to work with their (eligible) institution to develop an application for support.

o Applications are due on August 15, 2010. Applications will be peer-reviewed, and applicants will be notified of results by November 2010.

All applications must be submitted electronically. LRF allows up to 25 percent overhead. Smaller overhead amounts are preferred. To apply for these grant opportunities, please go to https://proposalcentral.altum.com

For more information, please call: (800) 235-6848

Excellence in Blood and Marrow Transplantation Award

Award: Monetary award of $1000 and a plaque.

Purpose: To recognize and support excellence in nurses engaged in blood and marrow transplantation

Nominee's Eligibility Criteria:
The candidate must meet the following criteria:

* Be a registered professional nurse and an active ONS member
* Have at least two years of oncology nursing experience
* Be a recognized expert in the field of blood and marrow transplantation (e.g., through publications, presentations, research, and peer review)
* Made a significant contribution to one or more of the following related to blood and marrow transplantation: professional/patient education, clinical practice, and/or nursing research
* Serves as a role model for other nurses.

Criteria:
The scoring criteria for judging this nomination is as follows:

* ONS involvement: Participation should include involvement at the local or national level.
o Includes membership on committees, holding office, or task force participation.
* Recognized expert in the field of blood and marrow transplantation, contributing to the development of blood and marrow transplantation.
o Includes articles in newsletters, journals, reports, video, multimedia, computer assisted instruction, chapters in books (do not include research here, include research in last criteria point).
* Significant contribution to the following areas:
o Professional/patient education related to blood and marrow transplantation
o Presentations
o Examples in letters of role modeling
o Specific educational interventions
o Program development
o Support groups
o Adjunct faculty to preceptor for students
o Community outreach
* Clinical practice related to blood and marrow transplantation:
o Theoretical concepts used
o Nursing process used
o Professional development of self and others
o Multidisciplinary collaboration
o Quality assurance
o Ethical decision-making used
o Reviews/applies nursing research
o Blood and marrow transplantation research

Application deadline: August 16, 2010, 5pm (ET).

For more information on any of the ONS awards, contact ONS at customer.service@ons.org. Both nominees and nominators will be notified once an application is received.

Oncology Nursing Society
125 Enterprise Drive Pittsburgh, PA15275
866-257-4ONS (866-257-4667)
412-859-6100
877-369-5497 (toll free fax)
412-859-6162 (fax)